Archive · 30 Dec 2025
Drug Regulator Cancels Import Licence for Hair-Loss Product
The Central Drugs Standard Control Organisation (CDSCO) in India has cancelled the import licence for a hair-loss product called QR678 Neo.
This product is a cosmetic and is made from plant-derived peptides.
The company that sells QR678 Neo claimed on its website that the product could treat various hair-loss conditions, such as hair loss after chemotherapy and other scalp issues.
However, the CDSCO said that cosmetics cannot claim to treat medical conditions.
The regulator found that the company's website had claims that were not approved, which violated the rules.
The company removed these claims after receiving a notice from the CDSCO, but the regulator still decided to cancel the import licence because the product was not registered as a drug or medical therapy.
The CDSCO cancelled the import licence for QR678 Neo, a hair-loss product.
QR678 Neo is a cosmetic product made from plant-derived peptides.
The company claimed the product could treat various hair-loss conditions, including post-chemotherapy hair loss.
The CDSCO found these claims to be false and misleading, violating cosmetic rules.
The company removed the claims after receiving a notice, but the regulator still cancelled the licence.
- Who
- Central Drugs Standard Control Organisation (CDSCO)
- What
- Cancelled the import licence for QR678 Neo, a hair-loss product
- When
- Not specified
- Where
- India
- Why
- The product made false and misleading claims about treating hair-loss conditions
- Product Name
- QR678 Neo
- Regulator
- Central Drugs Standard Control Organisation (CDSCO)
- Product Type
- Cosmetic
- Claimed Benefits
- Hair growth, thickness, and density
- Violation
- False and misleading claims
- Rule Violated
- Rule 36 of the cosmetic rules, 2020